Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 3
2005 7
2006 6
2007 3
2008 11
2009 8
2010 7
2011 9
2012 7
2013 13
2014 23
2015 18
2016 11
2017 10
2018 15
2019 10
2020 14
2021 16
2022 13
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C, Ayala R, Bilbao-Sieyro C, Chillón MC, Larráyoz MJ, Soria E, Aparicio-Pérez C, Bergua JM, Bernal T, Gil C, Tormo M, Algarra L, Alonso-Domínguez JM, Rodriguez-Arbolí E, Martínez-Sanchez P, Oliva A, Colorado-Araujo AM, Rodríguez-Medina C, Vives S, Hermosín L, Martínez-López J, García-Sanz R, Pérez-Simón JA, Calasanz MJ, Gómez-Casares MT, Barragán E, Sánchez-García J J, Montesinos P. De la Torre EP, et al. Among authors: perez simon ja. Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2023.284601. Online ahead of print. Haematologica. 2024. PMID: 38634126 Free article.
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, von dem Borne P, Snowden JA, Robinson S, Finazzi MC, Schroeder T, Collin M, Eder M, Forcade E, Loschi M, Bramanti S, Pérez-Simón JA, Czerw T, Polverelli N, Drozd-Sokolowska J, Raj K, Hernández-Boluda JC, McLornan DP. Robin M, et al. Bone Marrow Transplant. 2024 Mar 15. doi: 10.1038/s41409-024-02269-4. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38491198
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Front Immunol. 2024 Feb 7;15:1373852. doi: 10.3389/fimmu.2024.1373852. eCollection 2024. Front Immunol. 2024. PMID: 38384474 Free PMC article.
Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Front Immunol. 2024 Jan 16;14:1280580. doi: 10.3389/fimmu.2023.1280580. eCollection 2023. Front Immunol. 2024. PMID: 38292483 Free PMC article.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. Blood. 2024. PMID: 38194692 Free article. Clinical Trial.
ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, Jurado M, Martinez C, Natale A, Pérez-Simón JA, Brunello L, Avenoso D, Klein S, Ozkurt ZN, Herrera C, Wichert S, Chiusolo P, Gavriilaki E, Basak GW, Schoemans H, Koenecke C, Moiseev I, Peric Z. Penack O, et al. Front Immunol. 2023 Dec 11;14:1283034. doi: 10.3389/fimmu.2023.1283034. eCollection 2023. Front Immunol. 2023. PMID: 38149251 Free PMC article.
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro J, Boumendil A, Finel H, Bramanti S, Castagna L, Blaise D, Dominietto A, Kulagin A, Yakoub-Agha I, Tbakhi A, Solano C, Giebel S, Gulbas Z, López Corral L, Pérez-Simón JA, Díez Martín JL, Sanz J, Farina L, Koc Y, Socié G, Arat M, Jurado M, Bermudez A, Labussière-Wallet H, Villalba M, Ciceri F, Martinez C, Nagler A, Sureda A, Glass B. Montoro J, et al. Among authors: perez simon ja. Transplant Cell Ther. 2024 Feb;30(2):210.e1-210.e14. doi: 10.1016/j.jtct.2023.11.021. Epub 2023 Dec 1. Transplant Cell Ther. 2024. PMID: 38043802
192 results